L-Norvaline Reverses Cognitive Decline and Synaptic Loss in a Murine Model of Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The urea cycle is strongly implicated in the pathogenesis of Alzheimer's disease (AD). Arginase-I (ARGI) accumulation at sites of amyloid-beta (Aβ) deposition is associated with L-arginine deprivation and neurodegeneration. An interaction between the arginase II (ARGII) and mTOR-ribosomal protein S6 kinase β-1 (S6K1) pathways promotes inflammation and oxidative stress. In this study, we treated triple-transgenic (3×Tg) mice exhibiting increased S6K1 activity and wild-type (WT) mice with L-norvaline, which inhibits both arginase and S6K1. The acquisition of spatial memory was significantly improved in the treated 3×Tg mice, and the improvement was associated with a substantial reduction in microgliosis. In these mice, increases in the density of dendritic spines and expression levels of neuroplasticity-related proteins were followed by a decline in the levels of Aβ toxic oligomeric and fibrillar species in the hippocampus. The findings point to an association of local Aβ-driven and immune-mediated responses with altered L-arginine metabolism, and they suggest that arginase and S6K1 inhibition by L-norvaline may delay the progression of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 1×
“Chronic neuroinflammation is a prominent feature of AD pathogenesis (Heneka et al. 2015).”
BackgroundAβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938 · cited 2×
“Growing evidence indicates that soluble low weight Aβ oligomers and intermediate aggregates are the most neurotoxic forms of Aβ triggering synapse dysfunction and loss, and neuronal damage, which manifest consequentially in behavioral attributes of AD such as memory deficits (Walsh and Selkoe 2007).”
BackgroundNitric oxide in the central nervous system: neuroprotection versus neurotoxicity
Calabrese, V., Mancuso, C., Calvani, M., Rizzarelli, E., Butterfield, D. A., & Giuffrida Stella, A. M. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2214 · Cited by 1,543 · cited 2×
“Nitric oxide synthase (NOS) utilizes L-arginine as a substrate to produce NO and L-citrulline [27].”
BackgroundSystemic inflammation and disease progression in Alzheimer disease
Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., & Perry, V. H. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b6bb95 · Cited by 1,139 · cited 1×
“Likewise, it was suggested that inflammation correlates better with cognitive decline than accumulation of Aβ (Holmes et al. 2009).”
BackgroundSpangenberg, E. E., Lee, R. J., Najafi, A. R., Rice, R. A., Elmore, M. R. P., Blurton-Jones, M., West, B. L., & Green, K. N. (2016) · Brain · doi:10.1093/brain/aww016 · Cited by 695
Is Alzheimer’s disease a type 3 diabetes? A critical appraisal
Kandimalla, R., Thirumala, V., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.08.018 · Cited by 621
Abramov, A. Y., Canevari, L., & Duchen, M. R. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4042-03.2004 · Cited by 587
ARGINASE: A CRITICAL REGULATOR OF NITRIC OXIDE SYNTHESIS AND VASCULAR FUNCTION
Durante, W., Johnson, F. K., & Johnson, R. A. (2007) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2007.04638.x · Cited by 577 · cited 1×
“A growing body of evidence indicates that NO induces neuroprotection by triggering vasodilation and increasing the blood supply to neurons, thereby reducing their susceptibility to oxidative stress [29].”
BackgroundNew insights on the role of microglia in synaptic pruning in health and disease
Hong, S., Dissing-Olesen, L., & Stevens, B. (2016) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.12.004 · Cited by 557
Olmos-Alonso, A., Schetters, S. T. T., Sri, S., Askew, K., Mancuso, R., Vargas-Caballero, M., Holscher, C., Perry, V. H., & Gomez-Nicola, D. (2016) · Brain · doi:10.1093/brain/awv379 · Cited by 532
Tynan, R. J., Naicker, S., Hinwood, M., Nalivaiko, E., Buller, K. M., Pow, D. V., Day, T. A., & Walker, F. R. (2010) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.02.001 · Cited by 531
Olabarria, M., Noristani, H. N., Verkhratsky, A., & Rodríguez, J. J. (2010) · Glia · doi:10.1002/glia.20967 · Cited by 499 · cited 2×
“[78] reported an apparent reduction in the astrocytic somatic volume in the”
BackgroundFernández-Arjona, M. D. M., Grondona, J. M., Granados-Durán, P., Fernández-Llebrez, P., & López-Ávalos, M. D. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00235 · Cited by 417
Intracellular signaling in M‐CSF‐induced microglia activation: Role of Iba1
Imai, Y., & Kohsaka, S. (2002) · Glia · doi:10.1002/glia.10149 · Cited by 359 · cited 2×
“Iba1 is known to be expressed weakly by ramified microglia, however, upregulated and strongly expressed by activated microglia (Tynan et al. 2010), (Imai and Kohsaka 2002).”
BackgroundAbramov, A. Y., Canevari, L., & Duchen, M. R. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-12-05088.2003 · Cited by 337
Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease
Osborn, L. M., Kamphuis, W., Wadman, W. J., & Hol, E. M. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.001 · Cited by 312
Application of Metabolomics in Alzheimer’s Disease
Wilkins, J. M., & Trushina, E. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2017.00719 · Cited by 268
Janelsins, M. C., Mastrangelo, M. A., Oddo, S., LaFerla, F. M., Federoff, H. J., & Bowers, W. J. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-23 · Cited by 260
Bachstetter, A. D., Van Eldik, L. J., Schmitt, F. A., Neltner, J. H., Ighodaro, E. T., Webster, S. J., Patel, E., Abner, E. L., Kryscio, R. J., & Nelson, P. T. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0209-z · Cited by 258
Knight, E. M., Martins, I. V. A., Gümüsgöz, S., Allan, S. M., & Lawrence, C. B. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.02.010 · Cited by 232 · cited 2×
“An arm entry was counted when the hind paws of the mouse were entirely within the arm [39].”
MethodAstrocyte glutamine synthetase: pivotal in health and disease
Rose, C. F., Verkhratsky, A., & Parpura, V. (2013) · Biochemical Society Transactions · doi:10.1042/bst20130237 · Cited by 224
Lauritzen, I., Pardossi-Piquard, R., Bauer, C., Brigham, E., Abraham, J.-D., Ranaldi, S., Fraser, P., St-George-Hyslop, P., Le Thuc, O., Espin, V., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2775-12.2012 · Cited by 201 · cited 2×
“as the earliest βAPP catabolite and main contributor to the intracellular βAPP-related immunoreactivity in 3xTg mice, which is implicated in the neurodegenerative process and cognitive impairment taking place in this animal model of AD (Lauritzen et al. 2012).”
BackgroundKulijewicz‐Nawrot, M., Verkhratsky, A., Chvátal, A., Syková, E., & Rodríguez, J. J. (2012) · Journal of Anatomy · doi:10.1111/j.1469-7580.2012.01536.x · Cited by 160 · cited 2×
“Interestingly, the density of astrocytes remains relatively stable in the hippocampus, and cortices of the 3xTg mice for more than one year and is comparable to the non-Tg controls (Kulijewicz-Nawrot et al. 2012).”
BackgroundEndothelial nitric oxide deficiency promotes Alzheimer’s disease pathology
Austin, S. A., Santhanam, A. V., Hinton, D. J., Choi, D., & Katusic, Z. S. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12334 · Cited by 155 · cited 1×
“Another knockout (NOS3 −/−) mice model was shown to develop Alzheimer’s like pathology (Austin et al. 2013).”
BackgroundZanier, E. R., Fumagalli, S., Perego, C., Pischiutta, F., & De Simoni, M.-G. (2015) · Intensive Care Medicine Experimental · doi:10.1186/s40635-015-0039-0 · Cited by 147
Late-onset Alzheimer’s disease is associated with inherent changes in bioenergetics profiles
Sonntag, K.-C., Ryu, W.-I., Amirault, K. M., Healy, R. A., Siegel, A. J., McPhie, D. L., Forester, B., & Cohen, B. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-14420-x · Cited by 131 · cited 2×
“Additional hypothesis emphasizing impairment of bioenergetic metabolism as a key contributing mechanism to the pathogenesis of AD has been proposed recently (Sonntag et al. 2017).”
BackgroundRodríguez, J. J., Witton, J., Olabarria, M., Noristani, H. N., & Verkhratsky, A. (2010) · Cell Death & Disease · doi:10.1038/cddis.2009.2 · Cited by 114 · cited 1×
“Microglia are the first line of active immune defense in the brain, and an increase in microglial density is indicative of elevated pathogenic insults [52].”
BackgroundZanier, E. R., Marchesi, F., Ortolano, F., Perego, C., Arabian, M., Zoerle, T., Sammali, E., Pischiutta, F., & De Simoni, M.-G. (2016) · Journal of Neurotrauma · doi:10.1089/neu.2015.4041 · Cited by 94 · cited 2×
“To guarantee the selection of only cells present in the acquired field, for Iba1 staining, only cells with an area greater than 25 μm(2) were considered in the analysis, as widely accepted in the literature [55].”
MethodTargeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies.
Tramutola, A., Lanzillotta, C., & Di Domenico, F. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1244482 · Cited by 69 · cited 1×
“Consequently, inhibition of mTOR is a novel therapeutic target for AD [82].”
BackgroundEnhanced susceptibility of triple transgenic Alzheimer’s disease (3xTg-AD) mice to acute infection
Montacute, R., Foley, K., Forman, R., Else, K. J., Cruickshank, S. M., & Allan, S. M. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0826-5 · Cited by 43 · cited 1×
“This finding is in accordance with the literature [71].”
Result
Cited by
Astrocytes in human central nervous system diseases: a frontier for new therapies
Verkhratsky, A., Butt, A., Li, B., Illes, P., Zorec, R., Semyanov, A., Tang, Y., & Sofroniew, M. V. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01628-9 · Cited by 428
Neuroinflammation in Alzheimer’s Disease
Onyango, I. G., Jauregui, G. V., Čarná, M., Bennett, J. P., & Stokin, G. B. (2021) · Biomedicines · doi:10.3390/biomedicines9050524 · Cited by 330
Astrocytes in Alzheimer's disease: pathological significance and molecular pathways
Preman, P., Alfonso-Triguero, M., Alberdi, E., Verkhratsky, A., & Arranz, A. M. (2021) · Cells · doi:10.3390/cells10030540 · Cited by 176
Astrocytes in Alzheimer´s Disease: Pathological Significance and Molecular Pathways
Preman, P., Alfonso-Triguero, M., Alberdi, E., Verkhratsky, A., & Arranz, A. M. (2021) · doi:10.20944/preprints202102.0230.v1 · Cited by 176
Wang, Q., Lu, M., Zhu, X., Gu, X., Zhang, T., Xia, C., Yang, L., Xu, Y., & Zhou, M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113412 · Cited by 52
Metadata
- Authors
- Polis, B., Srikanth, K. D., Elliott, E., Gil-Henn, H., & Samson, A. O.
- Venue
- Neurotherapeutics
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 15
- Issue
- 4
- Pages
- 1036-1054
- ISSN
- 1878-7479 (ISSN-L)
- OpenAlex
- W2808843354
- Cited by
- 87
- References
- 30
- FWCI
- 5.34
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.